Cyclophosphamide
Chronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead CompanySmall moleculePhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Chronic Inflammatory Demyelinating Polyneuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
AMIFAMPRIDINE National Center for Research Resources (NCRR) | Phase 3 | BB |
HUMAN IMMUNOGLOBULINS National Center for Research Resources (NCRR) | Phase 3 | BB |
i10e Laboratoire français de Fractionnement et de Biotechnologies | Phase 3 | B |
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center | Phase 2 | CCC |
ETOPOSIDE Fred Hutchinson Cancer Center | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →